Edition:
United States

Flex Pharma Inc (FLKS.OQ)

FLKS.OQ on NASDAQ Stock Exchange Global Market

3.55USD
14 Dec 2017
Change (% chg)

$-0.01 (-0.28%)
Prev Close
$3.56
Open
$3.55
Day's High
$3.68
Day's Low
$3.55
Volume
5,728
Avg. Vol
9,030
52-wk High
$6.28
52-wk Low
$2.68

Latest Key Developments (Source: Significant Developments)

Flex Pharma Q3 loss per share $0.54
Monday, 6 Nov 2017 08:00am EST 

Nov 6 (Reuters) - Flex Pharma Inc ::Flex Pharma reports third quarter 2017 financial results.Q3 loss per share $0.54.Q3 revenue $414,000 versus I/B/E/S view $477,000.Q3 earnings per share view $-0.61 -- Thomson Reuters I/B/E/S.Flex Pharma Inc - ‍expects to have sufficient capital to fund operations into early 2019​.  Full Article

Flex Pharma reports positive topline data from exploratory phase 2 trial of FLX-787 in ALS
Monday, 6 Nov 2017 07:00am EST 

Nov 6 (Reuters) - Flex Pharma Inc :Flex Pharma reports positive topline data from exploratory phase 2 trial of FLX-787 in ALS.Flex Pharma - ‍data from exploratory phase 2 trial of FLX-787 showed statistically significant reduction in cramp-associated pain intensity & stiffness​.Flex Pharma Inc - ‍FLX-787 was generally well tolerated​.  Full Article

Flex Pharma initiates CMT phase 2 trial with FLX-787 in US
Monday, 16 Oct 2017 08:30am EDT 

Oct 16 (Reuters) - Flex Pharma Inc :Flex Pharma initiates CMT phase 2 trial with FLX-787 in US.Flex Pharma Inc - ‍ALS phase 2 trial currently underway​.Flex Pharma Inc - ‍expects to report topline results from this study in middle of 2018​.  Full Article

Flex Pharma Q2 loss per share $0.51
Wednesday, 2 Aug 2017 07:30am EDT 

Aug 2 (Reuters) - Flex Pharma Inc :Flex Pharma reports second quarter 2017 financial results.Q2 loss per share $0.51.Q2 revenue $336,000.Q2 revenue view $515,000 -- Thomson Reuters I/B/E/S.Q2 earnings per share view $-0.58 -- Thomson Reuters I/B/E/S.Flex Pharma Inc - expects to have "sufficient" capital to fund its operations into early 2019.  Full Article

Flex Pharma initiates ALS phase 2 trial with flx-787 in U.S.
Tuesday, 1 Aug 2017 07:30am EDT 

Aug 1 (Reuters) - Flex Pharma Inc :Flex Pharma initiates ALS phase 2 trial with flx-787 in us.Says expects to report topline results from this study in middle of 2018.Says also intends to initiate a phase 2 clinical trial in cmt this quarter.  Full Article

Flex Pharma names William Mcvicar president and chief executive officer
Monday, 31 Jul 2017 07:30am EDT 

July 31 (Reuters) - Flex Pharma Inc :Flex pharma names William Mcvicar president and chief executive officer.Flex Pharma Inc says are on track to initiate phase 2 clinical trials of flx-787 in both als and cmt this quarter in U.S..Flex Pharma Inc - appointed william mcvicar, ph.d. as president and chief executive officer of flex pharma.  Full Article

FDA grants fast track designation to Flex Pharma’s FLX-787
Tuesday, 25 Jul 2017 07:30am EDT 

July 25 (Reuters) - Flex Pharma Inc :FDA grants fast track designation to Flex Pharma’s FLX-787 for the treatment of severe muscle cramps associated with ALS.‍Phase 2 trials in ALS and CMT to commence in us this quarter​.‍Phase 2 trials in ALS and CMT to commence in us this quarter​.‍Prioritizing US phase 2 commend trial; exploratory Australian ALS study to end early​.  Full Article

Flex Pharma Inc says Christoph Westphal to step down as CEO
Monday, 5 Jun 2017 04:10pm EDT 

June 5 (Reuters) - Flex Pharma Inc : :Flex Pharma Inc - Christoph Westphal to step down as CEO and will continue as chair of board.Flex Pharma Inc - board appoints flex executive William Mcvicar as interim CEO.Flex Pharma Inc - Mcvicar joined Flex Pharma in April 2017 as president of research & development.  Full Article

Flex Pharma says US Phase 2 trial of FLX-787 in CMT patients to start this summer
Friday, 2 Jun 2017 08:00am EDT 

June 2 (Reuters) - Flex Pharma Inc :Flex Pharma’S Phase 2 trial with FLX-787 in charcot-marie-tooth endorsed by the inherited neuropathies consortium.Flex Pharma Inc says US Phase 2 trial of FLX-787 in CMT patients to start this summer.  Full Article

Flex Pharma Q1 loss per share $0.49
Wednesday, 3 May 2017 07:15am EDT 

May 3 (Reuters) - Flex Pharma Inc :Flex pharma reports first quarter 2017 financial results.Q1 loss per share $0.49.Q1 revenue $243,000.Q1 revenue view $350,000 -- Thomson Reuters I/B/E/S.Q1 earnings per share view $-0.62 -- Thomson Reuters I/B/E/S.Flex pharma inc- fda clears ind for flx-787 to commence us phase 2 trial in als.Flex pharma inc - fda clears ind for flx-787 to commence us phase 2 trial in als.Flex pharma inc- us phase 2 trials in als and cmt expected to commence summer 2017.Flex pharma inc - us phase 2 trials in als and cmt expected to commence summer 2017.Flex pharma inc - expects to have sufficient capital to fund its operations into early 2019.  Full Article

BRIEF-Flex Pharma Inc - ‍Completed Enrollment In Its Phase 2 Exploratory Spasticity Study In Multiple Sclerosis With Approximately 50 Patients In Australia​

* FLEX PHARMA INC - ‍COMPLETED ENROLLMENT IN ITS PHASE 2 EXPLORATORY SPASTICITY STUDY IN MULTIPLE SCLEROSIS WITH APPROXIMATELY 50 PATIENTS IN AUSTRALIA​ Source text for Eikon: Further company coverage: